Trial Information

Summary: Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO)

Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy

Patient Inclusion Criteria

• Cancer patients with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary
• Initiating a (new) course of chemotherapy with a minimum intent of 3 months therapy

PatientExclusionCriteria

Subject requiring systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic
• Patients at high risk of bleeding
• Severe renal impairment (estimated creatinine clearance < 30 mL/min)
• ECOG (Eastern Cooperative Oncology Group) performance status 3 & 4
• Known hypersensitivity to UFH or LMWH

If you would like to learn more about participating in this study, please send an e-mail message using the form below.